Clinical trial · no report yet · Phase 1
TIAN-SHAN1
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- NCT06905197 ↗
- Recruiting
- Dizal Pharmaceuticals
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- DZD6008; Sunvozertinib
- Arms
- Experimental: Part A Dose Escalation monotherapy cohorts (20 mg once daily [QD]) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (40 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (60 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (90 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (120 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (150 mg QD) · Experimental
- Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 1) · Experimental
- Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 2) · Experimental
- Experimental: Part A Dose Escalation Combination cohorts (Combination dose 3) · Experimental
- Experimental: Part B Dose Expansion cohort A1 (selected dose 1) · Experimental
- Experimental: Experimental: Part B Dose Expansion cohort A2 (selected dose 2) · Experimental
- Experimental: Experimental: Part B Dose Expansion cohort B1 (selected dose 1) · Experimental
- Experimental: Experimental: Part B Dose Expansion cohort B2 (selected dose 2) · Experimental
- Enrollment
- 140 (estimated)
- Primary outcomes
- Part A: To assess safety and tolerability
- Part A: To assess safety and tolerability
- Part B: To assess anti-tumor activity
- Sponsor
- Dizal Pharmaceuticals
- Start
- May 13, 2025
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06905197 · updated Feb 27, 2026